Fig. 1.

Response characteristics from combination TTFields and bevacizumab therapy. At the time of first recurrence, the tumor cyst measured 3.4 × 4.4 cm on gadolinium-enhanced T1-weighted (a) and FLAIR (b) images. After 2 cycles of bevacizumab, there was a partial decrease in the size of the cystic tumor to 1.9 × 3.6 cm as seen on gadolinium-enhanced T1-weighted images (c) and a partial resolution of the edema as detected on FLAIR (d) images. After 6 cycles of combination TTFields and bevacizumab therapy, there was a further decrease of the cystic tumor to 1.7 × 3.1 cm, or 65% reduction, as seen on gadolinium-enhanced T1-weighted images (e) and a resolution of edema as detected on FLAIR (f) images.